This study is an open-label study to evaluate and characterize test-retest reliability of [18F]florbetaben PET in subjects with AL-CA and ATTR-CA compared to non-CA subjects. Quantification of the [18F]florbetaben parameters related to the deposition of amyloid in the heart (such as Myocardial Tracer Retention (MTR) or Retention Index (RI)), and the variability in these parameters after repeated imaging will be evaluated. Measurement of blood metabolites and comparison of invasive with non-invasive quantification of [18F]florbetaben uptake in the heart will be performed.

开始日期2025-04-01

申办/合作机构

Life Molecular Imaging Ltd.

[+1]

NCT06600880

/ Not yet recruiting临床1期IIT

Neuronavigation-guided Focused Ultrasound-induced Blood-brain Barrier Opening in Alzheimer's Disease Patients and Its Effects on Brain Amyloid and Tau

The primary purpose of this phase 1b study is to further assess the safety and reversibility of focused ultrasound induced blood-brain barrier opening (FUS-BBBO) in participants with Alzheimer´s Disease (AD) using a single-element transducer with neuronavigation guidance. Preliminary results from our phase 1a study demonstrate that our neuronavigation-guided FUS system was capable of safely and transiently open the BBB in participants with AD. The information collected in this new study may be used to design future clinical trials to ultimately provide a viable alternative for treatment of AD in a safe and noninvasive manner.
Our secondary objective includes the assessment of the therapeutic efficacy of FUS-BBBO in reducing amyloid beta and neurofibrillary tangles, the main hallmark pathologies of AD, using PET tracers. Based on our preclinical studies in AD transgenic mouse models, FUS-BBBO alone was able to reduce both the amyloid beta and tau protein load, resulting in improvements in behavioral tasks assessing memory. Therefore, in this new study, the effect of FUS-BBBO on the amyloid beta and tau protein load in patients with AD will be assessed through the use of PET tracers.

开始日期2024-10-01

申办/合作机构

The Trustees of Columbia University in The City of New York

NCT05820191

/ Not yet recruiting临床2期IIT

B-amyloid as a Marker for GBM Bioimaging

This project is aimed at improvement of glioblastoma (GBM) diagnostic strategies for discrimination of tumor progression and chemo- and radiotherapeutic treatment-related changes in brain tissue. The study will elucidate the diagnostic value of PET imaging with use of amyloid-β radioisotope tracer Amyvid (Florbetapir F18) for GBM. The results of the study will provide data for development of new approach for GBM diagnostics.

开始日期2024-07-01

申办/合作机构

Universidad Central del Caribe, Inc.

[+1]

100 项与氟贝他吡[18F] 相关的临床结果

登录后查看更多信息

100 项与氟贝他吡[18F] 相关的转化医学

登录后查看更多信息

100 项与氟贝他吡[18F] 相关的专利（医药）

登录后查看更多信息

429

项与氟贝他吡[18F] 相关的文献（医药）

2025-02-01·Journal of Nutrition Health & Aging

Impact of diabetes on the progression of Alzheimer’s disease via trajectories of amyloid–tau–neurodegeneration (ATN) biomarkers

Article

作者: Kim, Eosu ; Kim, Eun Woo ; Kim, Keun You

BACKGROUND:

Alzheimer's disease (AD) is characterized by the accumulation of abnormal proteins, such as β-amyloid and tau, in the brain, which precedes cognitive impairment. Although diabetes mellitus (DM) is a well-established risk factor for AD, few studies have investigated how the presence of DM affects the sequential pathogenesis of AD, specifically within the amyloid-tau-neurodegeneration (ATN) and cognition framework.

OBJECTIVES:

This study aims to investigate the trajectories of ATN biomarkers in relation to the presence of DM in the preclinical and prodromal stages of AD.

DESIGN:

Participants with normal cognition (CN) or mild cognitive impairment (MCI) at baseline were included. Subjects were followed for 12-192 months, with neuroimaging and cognitive assessments conducted at every 12 or 24 months.

SETTING:

This study utilized data from the Alzheimer's Disease Neuroimaging Initiative (ADNI) database.

PARTICIPANTS:

A total of 603 participants aged 55-90 years were included, comprising 284 CN (25 with DM, 259 without DM) and 319 MCI (39 with DM, 280 without DM) individuals.

MEASUREMENTS:

ATN biomarkers were identified using florbetapir positron emission tomography (PET), flortaucipir PET, and magnetic resonance imaging (MRI), respectively. Cognition was assessed using the Clinical Dementia Rating-Sum of Boxes (CDR-SB) and Mini-Mental State Examination (MMSE). Moderation analysis was conducted to investigate the effect of DM on the association between ATN biomarkers of AD.

RESULTS:

Elevated amyloid standardized uptake value ratios (SUVRs) were associated with increased tau levels in the hippocampus, and this association was significantly enhanced by the presence of DM in MCI participants (p = 0.021). DM also strengthened the association between increased tau SUVR levels and neurodegeneration (indicated by decreased entorhinal cortical volumes; p = 0.005) in those with MCI. Furthermore, DM enhanced the association of decreased entorhinal (p = 0.012) and middle temporal cortex (p = 0.031) volumes with increased (worsened) CDR-SB scores in MCI participants. However, DM did not predict significant longitudinal changes in ATN pathology or cognitive decline in CN participants.

CONCLUSIONS:

Our study suggests that DM may increase the risk of AD by accelerating each step of the A-T-N cascade in the prodromal stage of AD, underscoring the importance of DM management in preventing the MCI conversion to AD.

2025-02-01·EUROPEAN ARCHIVES OF PSYCHIATRY AND CLINICAL NEUROSCIENCE

Associations of tau, Aβ, and brain volume of the Papez circuit with cognition in Alzheimer’s disease

Article

作者: Laraib, Azka ; Feng, Yuxue ; Li, Qin ; Li, Xiaofeng ; Lin, Xiuqi ; Zhan, Jiehong

This study aimed to investigate the cross-sectional associations between regional Alzheimer's disease (AD) biomarkers, including tau, β-amyloid (Aβ), and brain volume, within the Papez circuit, and neuropsychological functioning across the preclinical and clinical spectrum of AD. We utilized data from the Alzheimer's Disease Neuroimaging Initiative (ADNI) database, including 251 Aβ-positive participants. Participants were categorized into three groups based on the Clinical Dementia Rating (CDR): 73 individuals with preclinical AD (CDR = 0), 114 with prodromal AD (CDR = 0.5), and 64 with clinical AD dementia (CDR ≥ 1). Linear regression analyses, adjusted for age, gender, and education years, were employed to evaluate the associations between five regions of interest (the hippocampus, para-hippocampus, entorhinal cortex, posterior cingulate cortex, and thalamus) and five neuropsychological tests across the three imaging modalities. In the preclinical stage of AD, flortaucipir PET was associated with impaired global cognition and episodic memory (range standardized β = 0.255-0.498, p < 0.05 corrected for multiple comparisons), while florbetapir PET and brain volume were marginally related to global cognition (range standardized β = 0.221-0.231, p < 0.05). In the clinical stages of AD (prodromal and dementia), both increased flortaucipir uptake and decreased brain volume were significantly associated with poorer global neuropsychological and episodic memory performance (range standardized β = 0.222-0.621, p < 0.05, most regions of interest survived correction for multiple comparisions). However, a slight relationship was observed between florbetapir uptake and poorer global cognitive function. The regions most affected by flortaucipir PET were the hippocampus, para-hippocampus, and posterior cingulate cortex. During the clinical stages, the hippocampus and entorhinal cortex exhibited the most significant volumetric changes. Tau PET and brain volume measurements within the Papez circuit are more sensitive indicators of early cognitive deficits in AD than Aβ PET. Furthermore, during the clinical stages of AD, both flortaucipir PET and brain volume of the Papez circuit are closely correlated with cognitive decline. These findings underscore the importance of integrating multiple biomarkers for the comprehensive evaluation of AD pathology and its impact on cognition.

2025-01-01·STROKE

Do Amyloid Cerebral Deposits Influence the Long-Term Poststroke Cognitive Outcome?: The IDEA3 Study

Article

作者: Deramond, Hervé ; Wollenweber, Frank A. ; Loas, Gwénolé ; Marchal, Etienne ; Shields, Trevor ; Diouf, Momar ; Courselle-Arnoux, Audrey ; Picard, Carl ; Berrissoul, Hassan ; Despretz-Wannepain, Sandrine ; Barbay, M. ; Meyer, Marc-Etienne ; Trinchard, Niels ; Leclercq, Claire ; Lamy, Chantal ; Constans, Jean-Marc ; Canaple, Sandrine ; Roussel, Martine ; Godefroy, Olivier

BACKGROUND::

Although the presence of amyloid deposits is associated with a more severe cognitive status in patients with stroke at baseline, its influence on the subsequent cognitive outcome has not been extensively assessed. The primary objective of the present study of the IDEA3 (Imagerie des dépôts amyloïdes cérébraux par florbetapir AV-45 et diagnostic des déficits cognitifs et démence post Accident Vasculaire Cérébral) cohort was to determine the influence of amyloid positron emission tomography (PET) status on the 5-year cognitive outcome.

METHODS::

This longitudinal study performed in Amiens University Hospital (inclusions: October 2014 to October 2019; last visits: October 2018 to February 2023) has included 91 patients with stroke (ischemic stroke, 89%; hemorrhagic stroke, 11%) with florbetapir PET data at baseline (positive, n=14). Patients underwent annually comprehensive clinical and cognitive assessments for 5 years after the PET scan. The primary outcome was incident dementia; secondary outcomes were incident cognitive impairment, total prevalence of cognitive impairment, and modified Rankin Scale score.

RESULTS::

A survival analysis (mean poststroke follow-up, 80.4±27 months) showed that the incidence of incident dementia was higher in the PET-positive patients (odds ratio, 9.6 [95% CI, 2.5–36.9]; P =0.001), as was the incidence of incident cognitive impairment (odds ratio, 10 [95% CI, 1.9–52.3]; P =0.003). A Cox regression analysis showed that the association between amyloid status and the incidences of dementia ( P =0.001) and cognitive impairment ( P =0.007) was still significant after adjustment for age, education, prestroke modified Rankin Scale score and cognitive impairment, stroke type, and the PET status×stroke type interaction. Considering the overall prevalence at the last follow-up in the whole study population (n=91 patients), PET positivity was associated with an elevated risk of dementia (odds ratio, 6 [95% CI, 1.76–20.5]; P =0.002) and poststroke cognitive impairment (odds ratio, 6.25 [95% CI, 1.77–22]; P =0.002). The final modified Rankin Scale score did not differ ( P =0.3) according to PET status.

CONCLUSIONS::

Our results demonstrate the major impact of amyloid deposition on the stroke outcome and emphasized the need for comprehensive etiologic workup in patients with poststroke cognitive impairment.

REGISTRATION::

URL: https://www.clinicaltrials.gov ; Unique identifier: NCT02813434.

项与氟贝他吡[18F] 相关的新闻（医药）

2025-03-12

·PRNewswire

The ADDF's Diagnostics Accelerator Authors New Paper on Ocular Biomarker Landscape, Highlighting Ocular Tests as a Tool for Early Detection of Alzheimer's Disease

New findings published in Alzheimer's & Dementia suggest blood biomarkers are expected to become the standard method for diagnosing Alzheimer's, while ocular tests offer a non-invasive alternative for detecting at-risk patient populations NEW YORK, March 12, 2025 /PRNewswire/ -- The Alzheimer's Drug Discovery Foundation's (ADDF) Diagnostics Accelerator (DxA) authored a first-of-its-kind paper, "Unlocking ocular biomarkers for early detection of Alzheimer's disease," providing a landscape review of ocular biomarkers as another tool, alongside blood biomarkers, to aid in the early detection of Alzheimer's disease. The paper, which was published in Alzheimer's & Dementia, shares an informed perspective on the role of ocular biomarkers in the broader Alzheimer's diagnostics space and what defines a true ocular biomarker, while also highlighting the potential for ocular screening to identify at-risk patients who would otherwise go undiagnosed. The authors' assessment is based on hours of in-depth interviews with leading neurologists, ophthalmologists, optometrists, and primary care physicians from across the United States. Continue Reading ADDF x DxA Logo "Meaningful progress is being made in Alzheimer's research, with advances in novel biomarkers – including blood tests, retinal scans and digital tools – providing less invasive and more accessible ways to detect and diagnose Alzheimer's disease," said Howard Fillit, MD, Co-Founder and Chief Science Officer of the ADDF. "With the advent of these new tools, it is important to understand the appropriate context of use for each test. This paper shares a new and more nuanced perspective on the role of ocular biomarkers, which have the potential to identify at-risk individuals during routine eye exams, who otherwise may go undiagnosed." Blood-based testing for Alzheimer's is more cost-effective, convenient, and less invasive than current diagnostic methods and blood biomarkers are most likely to emerge as the standard clinical practice for Alzheimer's diagnostics. For patients to receive an Alzheimer's blood test, they must see their primary care doctor or a neurologist, which is not always accessible to all patients. As stated in the paper, the authors categorize ocular biomarkers as an additional non-invasive and accessible option to identify people at risk for Alzheimer's disease (e.g., pre-symptomatic) outside of the traditional settings of an annual physical or an exam with a neurologist. Ocular technologies are expected to cost between $100-200 of out-of-pocket costs and must meet minimum performance standards of 90-95% sensitivity and 75-85% specificity to qualify as a test for preclinical Alzheimer's. The authors believe focusing on these factors will help identify which of the four to eight million aging Americans who undergo an annual eye exam and who may be at risk for developing Alzheimer's. "This paper highlights the critical requirements and path to success of retinal biomarkers in Alzheimer's disease (AD) diagnosis", says Niranjan Bose, Managing Director, Health and Life Sciences at Gates Ventures. "While blood-based biomarkers are poised to take the lead in AD diagnostic applications, retinal biomarker testing can play a vital role in detecting preclinical AD and supporting differential diagnosis in neurodegenerative conditions. However, to make a meaningful impact in the future, it must meet rigorous technical standards similar to blood-based tests and demonstrate clinical utility to ensure integration as a reliable tool in early AD detection." Research into ocular biomarkers for detecting Alzheimer's disease is ongoing with early findings pointing to biomarkers in the retina as having the potential to provide key indicators of the disease. The retina displays similarities to the brain's cellular composition, and several neurodegenerative disorders are known to have manifestations in the retina. With ongoing technological advancements, ocular biomarkers have the potential to become a scalable, accessible tool that can be integrated into routine eye exams, making early detection of Alzheimer's disease more feasible and improving outcomes for at-risk individuals. "The pace of innovation in the Alzheimer's field has accelerated greatly in recent years, but major gaps persist, particularly in early, pre-symptomatic patient identification. Ocular biomarkers offer a novel method to detect the earliest molecular beginnings of Alzheimer's disease, and to do so with the potential for elevated sensitivity and without the burden of more invasive tests," said Sam Ulin, a Partner at ClearView Healthcare Partners who specializes in the translation of innovative technologies into clinical application. "Our work here with the DxA can hopefully serve as a guidepost to innovators in the space, helping them understand what is needed for an ocular biomarker test to meet the needs of patients and practitioners, maximizing the impact of these technologies on AD research, development, and ultimately, patient care." About The Alzheimer's Drug Discovery Foundation (ADDF) Founded in 1998 by Leonard A. and Ronald S. Lauder, the Alzheimer's Drug Discovery Foundation is dedicated to rapidly accelerating the discovery of drugs to prevent, treat and cure Alzheimer's disease. The ADDF is the only public charity solely focused on funding the development of drugs for Alzheimer's, employing a venture philanthropy model to support research in academia and the biotech industry. The ADDF's leadership and contributions to the field have played a pivotal role in bringing the first Alzheimer's PET scan (Amyvid®) and blood test (PrecivityAD®) to market, as well as fueling the current robust and diverse drug pipeline. Through the generosity of its donors, the ADDF has awarded more than $370 million to fund 765 Alzheimer's drug discovery programs, biomarker programs and clinical trials in 21 countries. To learn more, please visit: . ABOUT THE DIAGNOSTICS ACCELERATOR (DxA) The Diagnostics Accelerator, created in July 2018, is a $100 million global research initiative from partners including ADDF Co-Founder Leonard A. Lauder, Bill Gates, Jeff Bezos, MacKenzie Scott, the Dolby family, the Charles and Helen Schwab Foundation, The Association for Frontotemporal Degeneration, among others, to develop novel biomarkers for the early detection of Alzheimer's disease and related dementias. This research initiative is dedicated to accelerating the development of affordable and accessible biomarkers to diagnose Alzheimer's disease and related dementias and advance the clinical development of more targeted treatments. Through translational research awards and access to consulting support from industry experts, this program will challenge, assist and fund the research community in both academia and industry to develop novel peripheral and digital biomarkers. ABOUT CLEARVIEW HEALTHCARE PARTNERS ClearView is the leading independent strategy consulting firm focused on the life sciences. The Company was founded on the core belief that companies driving innovation in the life sciences need strategic partners that can combine deep scientific expertise, robust analytic approaches, and sound business instincts to create actionable and impactful results. These principles have enabled ClearView to build enduring partnerships with clients across the industry and around the globe, where we thrive in engagements where the stakes are high and the answer uncertain. ClearView meets these challenges with transparent problem-solving and dedicated thought partnership to create clarity on the path forward. For further information please visit . SOURCE Alzheimer's Drug Discovery Foundation WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

2025-03-06

·PRNewswire

Inaugural ADDF Scientific Summit Convenes Pioneering Scientists Leading and Shaping Alzheimer's Research

Daniel M. Skovronsky, MD, PhD, of Eli Lilly & Company, Receives Prestigious 2025 Melvin R. Goodes Prize, Nobel Prize of Alzheimer's Research Goodes Prize Winners Declare Future of Alzheimer's Treatment Will Rest on Combination Therapies and Precision Medicine NEW YORK and PALM BEACH, Fla., March 6, 2025 /PRNewswire/ -- The Alzheimer's Drug Discovery Foundation (ADDF) marked its Inaugural ADDF Scientific Summit in a momentous celebration of Alzheimer's science which brought together the most innovative and respected researchers in the field. The event, held on March 5th, featured the presentation of the esteemed Melvin R. Goodes Prize to Dr. Daniel M. Skovronsky, Chief Scientific Officer, Lilly, and President, Lilly Research Labs, and an address from Dr. Sanjay Gupta, CNN Chief Medical Correspondent, bestselling author, and practicing neurosurgeon. The Summit convened eight of the ten previous winners of the esteemed Goodes Prize for a symposium moderated by Dr. Niranjan Bose, Managing Director for Health & Life Sciences at Gates Ventures, spotlighting the cutting-edge advancements driving Alzheimer's therapeutics, biomarkers, and prevention, as well as the promising future of the field. These world-renowned scientists have each contributed novel ideas based around the biology of aging that are helping to revolutionize research. They, along with the ADDF, are leading and shaping the Alzheimer's field, propelling us toward combination therapies and precision medicine, the same strategy that has proven successful in cancer treatment. "It has been truly incredible to witness the pace of breakthroughs in Alzheimer's research over the past few years," said Dr. Howard Fillit, Co-Founder and Chief Science Officer of the ADDF. "Our trailblazing Goodes Prize recipients are catalyzing innovations that will enable us to tailor treatment approaches based on patients' individual biomarker profiles and combine drugs that target the specific causes of their disease. We are driving the next generation of care, which will use novel drugs targeting the underlying disease biology in tandem with current treatments to change the course of Alzheimer's." The Goodes Prize, recognized as the Nobel Prize of Alzheimer's research, is presented annually to a pioneering scientist to mark exceptional contributions to the Alzheimer's field. Skovronsky was recognized for his visionary work to develop critical diagnostic tests for Alzheimer's and for his leadership in developing and commercializing Kisunla, one of the first disease-modifying therapies for Alzheimer's patients. The game-changing diagnostics developed with Skovronsky's help include the Amyvid PET scan, the first FDA-approved diagnostic test for Alzheimer's which was developed with seed funding from the ADDF; the Tauvid PET scan, the first and only FDA-approved diagnostic for Tau in the brain; and a blood biomarker test for p-tau217 for the early diagnosis of Alzheimer's disease. "It is a profound honor to accept the 2025 Melvin R. Goodes Prize," said Skovronsky. "This recognition is a testament to the hard work and dedication of more than 35 years of Alzheimer's disease research to fight against this terrible disease. This award celebrates the power of collaboration and the unwavering commitment of the Alzheimer's Drug Discovery Foundation. Together, we can and will make history and change the world for patients everywhere." Skovronsky's work has been critical to the approvals of the first class of amyloid-targeting drugs for Alzheimer's, which offer patients options to delay disease progression for the first time and have set the foundation for the future of Alzheimer's therapies. As the next wave of therapeutics aimed at novel targets continues to advance, they can be combined with these anti-amyloids to increase efficacy and stop the disease in its tracks. "Six months ago, the ADDF celebrated the tenth anniversary of the Goodes Prize in Stockholm's City Hall, which is synonymous with the Nobel Prize. Now at our Inaugural ADDF Scientific Summit, we are once again highlighting the innovators driving progress in Alzheimer's on a global stage," said Ronald Lauder, Co-Founder and Co-Chairman of the ADDF. "Listening to our Goodes Prize scientists, it's amazing to hear how much progress has been made since my brother and I founded the ADDF in 1998 and to see the ADDF's fingerprints on the advancements we now take for granted – new drugs, new tests, and new prevention methods." Preceding the symposium, featured speaker Dr. Sanjay Gupta presented an address, highlighting the many reasons for hope as Alzheimer's science continues to make huge strides toward the next generation of treatments and prevention strategies. Gupta has earned multiple Emmy and Peabody awards for his health reporting and recently explored his own family history with Alzheimer's disease through filming a documentary, Dr. Sanjay Gupta Reports: The Last Alzheimer's Patient, which aired this past summer on CNN. "It was an honor to be a part of the ADDF's inaugural event celebrating its work for Alzheimer's patients," said Gupta. "We used to think about heart disease the way we thought about brain disease just a few years ago, as hopeless. But now that has changed. We can prevent heart disease, and thanks to exciting strides in how we treat and diagnose Alzheimer's, we will soon be able to prevent neurodegenerative diseases too. I am excited and I am optimistic about the future of Alzheimer's." About The Alzheimer's Drug Discovery Foundation (ADDF) Founded in 1998 by Leonard A. and Ronald S. Lauder, the Alzheimer's Drug Discovery Foundation is dedicated to rapidly accelerating the discovery of drugs to prevent, treat and cure Alzheimer's disease. The ADDF is the only public charity solely focused on funding the development of drugs for Alzheimer's, employing a venture philanthropy model to support research in academia and the biotech industry. The ADDF's leadership and contributions to the field have played a pivotal role in bringing the first Alzheimer's PET scan (Amyvid®) and blood test (PrecivityAD®) to market, as well as fueling the current robust and diverse drug pipeline. Through the generosity of its donors, the ADDF has awarded more than $370 million to fund 765 Alzheimer's drug discovery programs, biomarker programs and clinical trials in 21 countries. To learn more, please visit: . Media Contact: Emily Berkowitz, Senior Director of Communications, ADDF [email protected] 617-894-3540 SOURCE Alzheimer's Drug Discovery Foundation WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

2025-02-20

·PRNewswire

The Alzheimer's Drug Discovery Foundation Announces Daniel M. Skovronsky, MD, PhD, of Eli Lilly & Company, as Recipient of Prestigious 2025 Melvin R. Goodes Prize

Skovronsky will be recognized for his extraordinary work with the Amyvid PET scan, the first FDA-approved diagnostic test for Alzheimer's.The Goodes Prize – referred to the Nobel Prize of Alzheimer's research – honors scientists making extraordinary and lasting contributions to the Alzheimer's field. NEW YORK, Feb. 20, 2025 /PRNewswire/ -- The Alzheimer's Drug Discovery Foundation (ADDF) will present its 2025 Melvin R. Goodes Prize to Daniel M. Skovronsky, MD, PhD, Chief Scientific Officer, Lilly, and President, Lilly Research Labs, at the Inaugural ADDF Scientific Summit on Wednesday, March 5th. Skovronsky will be recognized for his groundbreaking work to develop critical diagnostic tests for Alzheimer's in addition to his leadership in developing and commercializing Kisunla, one of the first disease-modifying therapies for Alzheimer's patients. Continue Reading Daniel M. Skovronsky, MD, PhD, of Eli Lilly & Company, announced as the 2025 Melvin R. Goodes Prize The game-changing diagnostics developed with Skovronsky's help include the Amyvid PET scan, the first FDA-approved diagnostic test for Alzheimer's; the Tauvid PET scan, the first and only FDA-approved diagnostic for Tau in the brain; and a blood biomarker test for p-tau217 for the early diagnosis of Alzheimer's disease. The Goodes Prize, referred to as the Nobel Prize of Alzheimer's research, is presented annually to a leading scientist to mark exceptional contributions to the Alzheimer's field. This international award was established by the late Melvin R. Goodes to advance critical science aimed at fighting Alzheimer's disease and related dementias. "Dan is the epitome of a Goodes Prize awardee, a leading scientist who has advanced innovative and bold ideas to transform how we diagnose and develop new treatments for Alzheimer's," said Howard Fillit, MD, Co-Founder and Chief Science Officer at the ADDF. "The Goodes Prize emphasizes our ongoing commitment to accelerating drug development for Alzheimer's and honors the legacy of Mel Goodes, a trailblazer in the pharmaceutical industry. We are thrilled to recognize Dan's outstanding work and partnership with the ADDF, which spans more than 20 years. His efforts to develop the Amyvid PET scan made recent Alzheimer's drug approvals possible, including Lilly's Kisunla, and will benefit patients now and for years to come." The Amyvid PET scan, which received early seed funding from the ADDF, is a brain imaging test that helps detect Alzheimer's disease by combining a positron emission tomography (PET) scan and an injection of Amyvid, a radioactive tracer. Amyvid was instrumental in the approval of the first disease-modifying Alzheimer's drugs – Aduhelm in 2021, Leqembi in 2023, and Kisunla in 2024 – providing the biomarker data needed for regulatory approval. "Over the past decade, we have witnessed remarkable advances in Alzheimer's research," said Dr. Daniel Skovronsky, Chief Scientific Officer, Lilly, and President, Lilly Research Labs. "It is my belief that through early detection and early intervention we can someday make Alzheimer's a preventable disease. I am deeply honored to receive the prestigious Goodes Prize award and look forward to joining fellow recipients who are leading the way in developing new treatments for Alzheimer's. The early support from the ADDF for my work, which aimed to revolutionize how we diagnose patients to ensure the right ones were included in our studies, was crucial to advancing the field, and I will always be grateful for that support." The Goodes Prize, which celebrated its 10th anniversary last year in Stockholm with a program featuring Queen Silvia of Sweden and U.S. Ambassador to Sweden Erik Ramanathan, honors scientists who are leading new approaches to developing Alzheimer's therapeutics and diagnostics. "To have pioneering scientists like Dan who have received this award out there in the field, pushing research forward, is truly a gift," said Nancy Goodes, ADDF Board Member. "The breakthroughs being made in the name of the Goodes Prize are the most meaningful legacy for my husband." The 11th annual Goodes Prize will be presented at 6:00 p.m. ET on Wednesday, March 5, 2025 during the inaugural ADDF Scientific Summit. This celebration of Alzheimer's science will be hosted by Dr. Howard Fillit and features a keynote address from Dr. Sanjay Gupta, MD, CNN Chief Medical Correspondent, bestselling author and practicing neurosurgeon. The summit will highlight nine world-renowned scientists and recipients of the Melvin R. Goodes Prize discussing therapeutics, biomarkers, prevention, and what is coming next in the field. Skovronsky will be the latest to join the ranks of these accomplished scientists who have helped bring the biology of aging to the forefront of Alzheimer's research. "The Goodes Prize represents our mission to treat, prevent, and ultimately cure Alzheimer's disease," commented Mark Roithmayr, ADDF Chief Executive Officer. "We support one of the largest and most diverse clinical development portfolios for Alzheimer's disease, and pioneering research, like Dan's, is critical to our goal of driving meaningful innovation and change in drug development." The Melvin R. Goodes Prize for Excellence in Drug Development was established in 2015 in honor of Melvin R. Goodes, former CEO of Warner-Lambert Company, who channeled his unique knowledge of the drug industry into Alzheimer's advocacy after being diagnosed with the disease. The award recognizes individual researchers whose work has significantly advanced our understanding of Alzheimer's, paving the way for potential breakthroughs in treatment and prevention. Previous Goodes Prize recipients have demonstrated tremendous innovation and perseverance in the quest for effective treatment options for Alzheimer's. Internationally lauded as the highest recognition in Alzheimer's research, the Goodes Prize has helped move the field forward by facilitating thought provoking discussions among leading scientists from academia, industry, and philanthropy in pursuit of a future free of Alzheimer's. About The Alzheimer's Drug Discovery Foundation (ADDF) Founded in 1998 by Leonard A. and Ronald S. Lauder, the Alzheimer's Drug Discovery Foundation is dedicated to rapidly accelerating the discovery of drugs to prevent, treat and cure Alzheimer's disease. The ADDF is the only public charity solely focused on funding the development of drugs for Alzheimer's, employing a venture philanthropy model to support research in academia and the biotech industry. The ADDF's leadership and contributions to the field have played a pivotal role in bringing the first Alzheimer's PET scan (Amyvid®) and blood test (PrecivityAD®) to market, as well as fueling the current robust and diverse drug pipeline. Through the generosity of its donors, the ADDF has awarded more than $370 million to fund 765 Alzheimer's drug discovery programs, biomarker programs and clinical trials in 21 countries. To learn more, please visit: . SOURCE Alzheimer's Drug Discovery Foundation WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

100 项与氟贝他吡[18F] 相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D09617	氟贝他吡[18F]	V09AX05	DB09149

研发状态

批准上市

10 条最早获批的记录,

后查看更多信息

适应症	国家/地区	公司	日期
阿尔茨海默症	欧盟	Eli Lilly Nederland BV	2013-01-14
阿尔茨海默症	冰岛	Eli Lilly Nederland BV	2013-01-14
阿尔茨海默症	列支敦士登	Eli Lilly Nederland BV	2013-01-14
阿尔茨海默症	挪威	Eli Lilly Nederland BV	2013-01-14
造影剂	美国	Avid Radiopharmaceuticals, Inc.	2012-04-06

未上市

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
阿尔茨海默病引起的痴呆症	临床3期	中国	南京江原安迪科正电子研究发展有限公司	2022-10-20
认知功能障碍	临床3期	美国	Avid Radiopharmaceuticals, Inc.	2011-07-01
轻度认知障碍	临床3期	-	Avid Radiopharmaceuticals, Inc.	2011-02-01
慢性创伤性脑病	临床2期	美国	Avid Radiopharmaceuticals, Inc.	2014-06-01
路易体病	临床2期	美国	Avid Radiopharmaceuticals, Inc.	2010-03-01
额颞痴呆	临床2期	英国	Avid Radiopharmaceuticals, Inc.	2009-09-01
帕金森病	临床2期	美国	Avid Radiopharmaceuticals, Inc.	2009-01-01

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT04118764 (CTgov)	N/A	阿尔茨海默症	6	Neuronavigation-guided single-element focused ultrasound transducer+Amyvid+Definity	憲鬱艱蓋衊鏇觸遞願獵 = 餘醖積網鹹齋艱艱鏇醖憲繭憲範觸築鹽鑰簾壓 (顧選遞網鏇獵壓壓艱鏇, 糧製壓願顧觸膚範膚積 ~ 選繭廠構簾鏇鏇齋觸選) 更多	-	2024-08-26
SNMMI2024	N/A	-	-	Active tACS	鑰窪淵廠積鏇構製製憲(積鏇鑰獵鑰憲構膚夢廠) = 壓糧衊淵醖膚膚範範簾築襯憲顧繭夢範齋齋製 (簾鑰襯願襯鹹淵範構蓋 )	-	2024-06-09
SNMMI2024	N/A	-	-	Sham tACS	鑰窪淵廠積鏇構製製憲(積鏇鑰獵鑰憲構膚夢廠) = 醖鏇網築廠餘繭鏇壓鏇築襯憲顧繭夢範齋齋製 (簾鑰襯願襯鹹淵範構蓋 )	-	2024-06-09
SNMMI2022	N/A	-	-	Random Forest	鬱選鬱鹹獵糧簾齋顧選(鹽鏇繭鏇膚鏇鏇範製鏇) = 鑰蓋衊餘鹽製窪餘網糧醖艱膚憲淵餘窪築壓獵 (積淵襯鏇鹹鑰襯鹹遞醖 ) 更多	-	2022-08-08
SNMMI2022	N/A	-	-	Random Forest (K-Means Clustering)	鬱選鬱鹹獵糧簾齋顧選(鹽鏇繭鏇膚鏇鏇範製鏇) = 窪憲艱淵範觸衊網鑰積醖艱膚憲淵餘窪築壓獵 (積淵襯鏇鹹鑰襯鹹遞醖 ) 更多	-	2022-08-08
NCT01683825 (CTgov)	临床4期	老年性心脏淀粉样变性	23	florbetapir+F	鬱廠鹽願壓構築築糧鹽(簾齋鹹蓋觸夢夢醖襯簾) = 膚膚鹽鏇蓋糧簾襯觸艱構鬱顧鬱顧鏇鏇淵構鑰 (廠繭選選淵觸夢齋鹹膚, 願鑰鑰網獵艱鑰獵窪憲 ~ 糧齋鏇鬱憲簾製選淵夢) 更多	-	2022-04-13
NCT01767493 (CTgov)	临床4期	复发-缓解型多发性硬化	19	[18F]Florbetapir PET imaging	築淵壓鏇顧繭淵構夢繭 = 鏇鬱窪顧襯餘顧壓糧願積繭鬱鏇築顧膚簾積構 (築構餘醖鏇簾顧製糧簾, 構鏇鏇築築繭襯壓構艱 ~ 築膚鑰範鏇醖製願鬱艱) 更多	-	2021-08-27
AAIC2018	N/A	阿尔茨海默症 amyloid beta (Aβ)	-	[18F]FLORBETAPIR (AD patients)	選構願範餘夢鹹淵壓選(構醖鏇網鹹夢淵廠繭願) = 艱憲遞獵夢遞鹹襯膚膚餘襯餘壓餘艱鑰顧構憲 (壓繭壓範壓夢膚窪製鹽 )	-	2018-07-01
AAIC2018	N/A	阿尔茨海默症 amyloid beta (Aβ)	-	[18F]FLORBETAPIR (Controls)	選構願範餘夢鹹淵壓選(構醖鏇網鹹夢淵廠繭願) = 餘鹽積繭鬱衊壓憲壓餘餘襯餘壓餘艱鑰顧構憲 (壓繭壓範壓夢膚窪製鹽 )	-	2018-07-01
NCT01518374 (CTgov)	临床2期	阿尔茨海默症 \| 轻度认知障碍	1,768	Florbetapir F 18	壓構糧襯餘築壓艱觸繭 = 範壓顧鹽積糧製範襯壓夢鏇築夢夢鏇齋鑰繭鏇 (遞淵夢觸膚壓鑰選襯鏇, 憲鏇築積壓艱糧鬱鏇鬱 ~ 艱夢夢醖憲觸鑰鑰鑰壓) 更多	-	2018-06-14
SNMMI2016	N/A	阿尔茨海默症	-	Amyloid PET Tracer (AD Patients)	網繭簾艱築獵餘鏇窪範(築網艱鹹艱膚廠積夢鏇) = Receiver Operating Characteristics (ROC) showed the Area-under-the-ROC-Curve of 0.90±0.018 using 3D-SSP-PCLD and 0.91±0.018 3D-SSP-SUVR, indicating a nearly identical discriminatory power for normal controls vs AD patients 膚獵衊鬱範糧鏇繭網醖 (顧繭壓鑰襯窪鑰窪構糧 ) 更多	-	2016-05-24
ISC2016	N/A	脑淀粉样血管病	-	Florbetapir (CAA patients)	遞簾襯齋獵觸獵鹽襯蓋(餘夢鏇餘壓構鑰鬱鹹鑰) = 蓋醖糧鏇顧鬱網積願襯鹹構網鏇窪鏇艱淵憲鏇 (積襯鹹蓋壓鹽糧齋積獵 )	-	2016-02-01
ISC2016	N/A	脑淀粉样血管病	-	Florbetapir (HTN-ICH patients)	遞簾襯齋獵觸獵鹽襯蓋(餘夢鏇餘壓構鑰鬱鹹鑰) = 醖鏇製餘鏇壓範築艱窪鹹構網鏇窪鏇艱淵憲鏇 (積襯鹹蓋壓鹽糧齋積獵 )	-	2016-02-01
CTAD2015	N/A	-	-	Genentech Tau Probe 1 ([18F]GTP1)	製鏇衊鏇獵艱簾鹹蓋齋(製顧構糧願鏇襯壓願餘) = 築製範鹹夢糧製廠遞襯願窪淵憲襯繭襯廠壓製 (憲憲餘壓簾鑰憲鬱鹹窪, 4.3)	-	2015-11-04